1UC Stock Overview
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Cue Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$2.82 |
| 52 Week Low | US$0.31 |
| Beta | 1.8 |
| 11 Month Change | -29.79% |
| 3 Month Change | 53.49% |
| 1 Year Change | -53.43% |
| 33 Year Change | -90.39% |
| 5 Year Change | -90.92% |
| Change since IPO | -89.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1UC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -0.2% | 0.8% |
| 1Y | -53.4% | -16.9% | 9.1% |
Return vs Industry: 1UC underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 1UC underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 1UC volatility | |
|---|---|
| 1UC Average Weekly Movement | 25.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1UC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1UC's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Cue Biopharma, Inc. Fundamentals Summary
| 1UC fundamental statistics | |
|---|---|
| Market cap | €64.10m |
| Earnings (TTM) | -€42.58m |
| Revenue (TTM) | €9.10m |
7.2x
P/S Ratio-1.5x
P/E RatioIs 1UC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1UC income statement (TTM) | |
|---|---|
| Revenue | US$9.53m |
| Cost of Revenue | US$37.29m |
| Gross Profit | -US$27.76m |
| Other Expenses | US$16.85m |
| Earnings | -US$44.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | -291.24% |
| Net Profit Margin | -468.02% |
| Debt/Equity Ratio | 20.9% |
How did 1UC perform over the long term?
See historical performance and comparison